Cartesian Therapeutics announced its Q3 2026 financial results and business updates, highlighting progress in its Phase 3 AURORA trial of Descartes-08 for myasthenia gravis (MG) with data expected in Q1 2027 and a planned biologics license application filing in mid-2027. Retreatment data showed strong, durable patient responses with no new safety issues. The company is also advancing Phase 2 and Phase 1/2 trials for myositis and juvenile dermatomyositis, with data expected in the first half of 2027. Cartesian reported a net loss of $11.5 million for Q3 but holds $124.7 million in cash to support operations into 2028, preparing for potential commercial launch.
Cartesian Therapeutics' Q3 2026 financial results and business updates provide context for readers. For those following the health sector, 94 of 150 priced US health stocks rose while 48 fell. Notable movers include Edwards Lifesciences Corporation at USD 102.74 with a 3.39% increase and a typical hold time on Pluang of 0 days, LifeStance Health Group Inc. at USD 14.67 with a 3.24% rise and a typical hold time of 13 days, and Cigna Corp at USD 315.00 with a 3.14% gain and 100% buy order activity. This data is as of Nov 05, 2026 19:01 WIB.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
